These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29759964)

  • 1. Risk of fragility fracture among patients with gout and the effect of urate-lowering therapy.
    Sultan AA; Whittle R; Muller S; Roddy E; Mallen CD; Bucknall M; Helliwell T; Hider S; Paskins Z
    CMAJ; 2018 May; 190(19):E581-E587. PubMed ID: 29759964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy.
    Sultan AA; Muller S; Whittle R; Roddy E; Mallen C; Clarson L
    CMAJ; 2019 Jun; 191(22):E597-E603. PubMed ID: 31160496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study.
    Dennison EM; Rubin KH; Schwarz P; Harvey NC; Bone KW; Cooper C; Abrahamsen B
    Arch Osteoporos; 2015; 10():36. PubMed ID: 26481934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
    Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
    Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis.
    Kuo CF; Grainge MJ; Mallen C; Zhang W; Doherty M
    Rheumatology (Oxford); 2015 Dec; 54(12):2145-50. PubMed ID: 26170376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uricosuric medications for chronic gout.
    Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010457. PubMed ID: 25392987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allopurinol initiation and all-cause mortality in the general population.
    Dubreuil M; Zhu Y; Zhang Y; Seeger JD; Lu N; Rho YH; Choi HK
    Ann Rheum Dis; 2015 Jul; 74(7):1368-72. PubMed ID: 24665118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of hyperuricemia, gout, and UA-lowering therapy with the risk of fractures: A meta-analysis of observational studies.
    Zong Q; Hu Y; Zhang Q; Zhang X; Huang J; Wang T
    Joint Bone Spine; 2019 Jul; 86(4):419-427. PubMed ID: 30910706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.
    Vargas-Santos AB; Peloquin CE; Zhang Y; Neogi T
    JAMA Intern Med; 2018 Nov; 178(11):1526-1533. PubMed ID: 30304329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
    Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
    [No Abstract]   [Full Text] [Related]  

  • 14. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study.
    Kok VC; Horng JT; Chang WS; Hong YF; Chang TH
    PLoS One; 2014; 9(6):e99102. PubMed ID: 24897240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gout is not associated with the risk of fracture: a meta-analysis.
    Liu F; Dong J; Zhou D; Kang Q; Xiong F
    J Orthop Surg Res; 2019 Aug; 14(1):272. PubMed ID: 31455330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy.
    Drivelegka P; Sigurdardottir V; Svärd A; Jacobsson LTH; Dehlin M
    Arthritis Res Ther; 2018 Jun; 20(1):108. PubMed ID: 29855389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
    Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
    Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
    [No Abstract]   [Full Text] [Related]  

  • 20. [Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].
    Soós B; Szamosi S; Benkő S; Paragh G; Szekanecz Z
    Orv Hetil; 2018 Oct; 159(40):1625-1636. PubMed ID: 30277413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.